The Next Chokepoint: China’s Leverage Over US Pharmaceutical Inputs

China’s tightening grip over critical mineral supply chains has long posed strategic risks to the United States. But Beijing’s expanding control over pharmaceutical ingredients may prove even more dangerous. In recent years, Chinese exporters have quietly pumped unregulated and frequently counterfeit active pharmaceutical ingredients (APIs) into America, exploiting gaps in US law and Washington’s sluggish implementation of drug-tracking requirements. These schemes—often involving mislabeled packages and gray-market distributors—have already resulted in hospitalizations and deaths, revealing how China’s leverage over essential medical inputs directly threatens Americans’ health and safety. As with minerals and manufacturing, the Chinese Communist Party is increasingly using its control over APIs to undermine US interests. Policymakers should move quickly to strengthen oversight, close loopholes in the pharmaceutical supply chain, and shift critical API production back to trusted domestic sources. To discuss how America can restore its sovereignty in pharmaceuticals, Michael Sobolik will host Former US Representative Ted Yoho and an expert panel.